News provided byRedHill Biopharma Ltd. Apr 08, 2024, 09:23 ETShare this article RedHill continues corporate transformation to focus on U.S. government-funded pipeline development in underserved, sizeable therapeutic areas with a disciplined cost-base...
In September 2021 RedHill Biopharma Inc., AstraZeneca AB, AstraZeneca Pharmaceuticals LP and Nektar Therapeutics entered into a settlement and license agreement with Aurobindo Pharma USA, Inc. resolving their patent litigation in the U.S. in response to Aurobindo's Abbreviate...
专业生物制药公司RedHill Biopharma Ltd.(纳斯达克股票代码:RDHL)宣布与Cosmo Pharmaceuticals NV(SIX证券交易所股票代码:COPN)签署了一项生产协议,进一步扩大opaganib(Yeliva®,ABC294640)的生产能力,以满足可能得到全球紧急使用授权后出现的预期需求。 Opaganib旨在用于广泛对抗与突刺蛋白突变无关的不同的病毒株。Opaganib...
特种制药企业RedHill Biopharma Ltd.(Nasdaq: RDHL)宣布,该公司在美国进行的opaganib(Yeliva®, ABC294640)用于新冠肺炎住院患者口服治疗的2期研究的初步顶线数据显示出积极的安全性和有效性信号。 这项随机、双盲、安慰剂对照的opaganib(NCT04414618)美国2期概念验证研究招募了40名需要输氧的患者。这项研究不追求统计...
RedHill is at the forefront of pandemic preparedness and medical countermeasures efforts, developing two novel, potentially broad-acting, host-directed, late-stage, oral, small molecule therapies, with intrinsic viral mutation-resistant properties, suitable for stockpiling and easy distribution and administ...
RedHill Biopharma Secures U.S. Government Funding through BARDA to Advance Opaganib for Ebola Treatment Read More October 1, 2024 RedHill and Medi-Cal Deal Maintains Talicia® Reimbursement Without Prior Authorization for 15 Million Californians ...
今天,RedHill Biopharma公司(http://www.maoyihang.com/company/)宣布,美国FDA批准其创新疗法Talicia上市,用于治疗感染幽门螺杆菌的成人患者。 Talicia是一款获得FDA批准的基于利福布汀(rifabutin)的幽门螺杆菌清除疗法,旨在解决幽门螺杆菌对标准护理疗法中常用抗生素的耐药性问题。
以色列特拉维夫和北卡罗来纳罗利, Oct. 15, 2020 (GLOBE NEWSWIRE) -- 特种生物制药企业RedHill Biopharma Ltd.(Nasdaq:RDHL)(以下称“RedHill”或“公司”)今天宣布与欧洲和加拿大的两家专业制药厂商合作以推进opaganib的生产。针对这种新药治疗重症新冠肺炎的全球范围...
News provided by RedHill Biopharma Ltd. Nov 27, 2023, 07:00 ET Share this article The U.S. FDA has granted five years' market exclusivity for Talicia under the Generating Antibiotic Incentives Now (GAIN) Act Qualified Infectious Disease ...
导读:生物制药公司RedHillBiopharma(RedHill)宣布其抗生素药物Talicia获FDA批准上市。 2019年11月18日,动脉网(微信号:vcbeat)通过外媒资讯获悉,生物制药公司RedHillBiopharma(RedHill)宣布其抗生素药物Talicia获FDA批准上市,用于治疗感染幽门螺杆菌的成人患者,以降低幽门螺杆菌致胃癌的风险,并解决该细菌对抗生素的耐药性问题。